These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34046088)

  • 1. Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program.
    Monteiro FSM; Silva AGE; Gomes AJPS; Dutra C; Ferreira NO; Mariano RC; Schutz FA
    Ther Adv Med Oncol; 2021; 13():17588359211015499. PubMed ID: 34046088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.
    Rouvinov K; Levanon E; Peer A; Sarfaty M; Sarid D; Neiman V; Grikshtas E; Rosenbaum E; Kushnir I; Talmor B; Friger M; Zarbiv Y; Gez E; Dresler H; Shalata W; Meirovitz A; Shrem NS; Yakobson A; Mermershtain W; Keizman D
    Front Oncol; 2023; 13():1151701. PubMed ID: 37293597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma.
    Sayegh N; Tripathi N; Agarwal N; Swami U
    Onco Targets Ther; 2022; 15():1047-1055. PubMed ID: 36186154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
    Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma.
    Van Sanden S; Youssef A; Baculea S; Stubbs K; Triantos S; Yuan Z; Daly C
    J Health Econ Outcomes Res; 2024; 11(2):49-57. PubMed ID: 39267886
    [No Abstract]   [Full Text] [Related]  

  • 6. FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.
    Adib E; El Zarif T; Jain RK; Skelton WP; Freeman D; Curran C; Akl E; Nassar AH; Ravi P; Mantia C; Kwiatkowski DJ; Choueiri TK; Sonpavde G
    BJUI Compass; 2022 Mar; 3(2):169-172. PubMed ID: 35224552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Loriot Y; O'Hagan A; Siefker-Radtke AO
    Future Oncol; 2024 Feb; 20(5):231-243. PubMed ID: 37916514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis.
    Zheng X; Wang H; Deng J; Yao M; Zou X; Zhang F; Ma X
    Front Oncol; 2022; 12():907377. PubMed ID: 36776367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.
    Yuan T; Li F; Hou Y; Guo H
    Front Pharmacol; 2023; 14():1266890. PubMed ID: 38074150
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
    Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Qi K; Akapame S; Triantos S; O'Hagan A; Loriot Y
    Eur Urol Open Sci; 2023 Apr; 50():1-9. PubMed ID: 37101768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.
    Benjamin DJ; Mar N; Rezazadeh Kalebasty A
    Clin Med Insights Oncol; 2022; 16():11795549221126252. PubMed ID: 36186672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review.
    Smith KER; Hitron EE; Russler GA; Baumgarten DA; Bilen MA
    J Immunother Precis Oncol; 2020 Feb; 3(1):23-26. PubMed ID: 35756183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    D'Angelo A; Bagby S; Galli IC; Bortoletti C; Roviello G
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1139-1146. PubMed ID: 32935605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
    Perez-Gracia JL; Loriot Y; Rosenberg JE; Powles T; Necchi A; Hussain SA; Morales-Barrera R; Retz MM; Niegisch G; Durán I; Théodore C; Grande E; Shen X; Wang J; Nelson B; Derleth CL; van der Heijden MS
    Eur Urol; 2018 Mar; 73(3):462-468. PubMed ID: 29273410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erdafitinib to treat urothelial carcinoma.
    Hanna KS
    Drugs Today (Barc); 2019 Aug; 55(8):495-501. PubMed ID: 31461086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib.
    de Almeida Carvalho LM; de Oliveira Sapori Avelar S; Haslam A; Gill J; Prasad V
    JAMA Netw Open; 2019 Nov; 2(11):e1916091. PubMed ID: 31755953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.